| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pulmonary Disease, Chronic Obstructive | 32 | 2023 | 149 | 8.920 |
Why?
|
| Prostatic Neoplasms | 57 | 2024 | 935 | 7.930 |
Why?
|
| Prostatectomy | 39 | 2023 | 63 | 7.220 |
Why?
|
| Asthma | 26 | 2023 | 380 | 6.540 |
Why?
|
| Urinary Bladder Neoplasms | 16 | 2024 | 63 | 4.710 |
Why?
|
| Prostate-Specific Antigen | 26 | 2024 | 118 | 4.320 |
Why?
|
| Robotics | 14 | 2023 | 41 | 4.120 |
Why?
|
| Kidney Transplantation | 12 | 2020 | 86 | 3.740 |
Why?
|
| Humans | 251 | 2024 | 37093 | 3.730 |
Why?
|
| Lung Diseases | 10 | 2019 | 61 | 3.570 |
Why?
|
| Kidney Neoplasms | 15 | 2024 | 68 | 3.340 |
Why?
|
| Occupational Exposure | 13 | 2023 | 79 | 3.340 |
Why?
|
| Male | 178 | 2024 | 20025 | 3.320 |
Why?
|
| Forced Expiratory Volume | 22 | 2022 | 70 | 3.160 |
Why?
|
| Adiponectin | 8 | 2014 | 55 | 3.000 |
Why?
|
| Air Pollution, Indoor | 5 | 2022 | 41 | 2.960 |
Why?
|
| Occupational Diseases | 7 | 2021 | 47 | 2.890 |
Why?
|
| Smoking | 21 | 2020 | 940 | 2.820 |
Why?
|
| Postoperative Complications | 21 | 2023 | 210 | 2.800 |
Why?
|
| Middle Aged | 118 | 2024 | 10129 | 2.720 |
Why?
|
| Uranium | 5 | 2021 | 21 | 2.680 |
Why?
|
| Aged | 96 | 2024 | 6741 | 2.600 |
Why?
|
| Neoplasm Recurrence, Local | 12 | 2023 | 128 | 2.510 |
Why?
|
| Lung | 16 | 2023 | 446 | 2.430 |
Why?
|
| Laparoscopy | 14 | 2018 | 54 | 2.360 |
Why?
|
| Cystectomy | 12 | 2022 | 12 | 2.330 |
Why?
|
| Obesity | 15 | 2022 | 1067 | 2.310 |
Why?
|
| Carcinoma, Transitional Cell | 10 | 2024 | 18 | 2.210 |
Why?
|
| Mining | 4 | 2020 | 18 | 2.210 |
Why?
|
| Female | 119 | 2024 | 20969 | 2.160 |
Why?
|
| Nephrectomy | 10 | 2018 | 23 | 2.110 |
Why?
|
| Prostate | 11 | 2024 | 154 | 1.850 |
Why?
|
| United States | 57 | 2024 | 4223 | 1.850 |
Why?
|
| Adult | 74 | 2023 | 11712 | 1.820 |
Why?
|
| Treatment Outcome | 30 | 2023 | 1369 | 1.800 |
Why?
|
| Biomass | 4 | 2018 | 54 | 1.790 |
Why?
|
| Bronchitis, Chronic | 5 | 2022 | 15 | 1.790 |
Why?
|
| Carcinoma, Renal Cell | 9 | 2023 | 36 | 1.770 |
Why?
|
| Body Mass Index | 14 | 2018 | 854 | 1.740 |
Why?
|
| Spirometry | 11 | 2021 | 33 | 1.720 |
Why?
|
| Retrospective Studies | 37 | 2024 | 2026 | 1.660 |
Why?
|
| Risk Assessment | 15 | 2023 | 753 | 1.620 |
Why?
|
| New Mexico | 14 | 2021 | 31 | 1.570 |
Why?
|
| Surgical Procedures, Operative | 5 | 2017 | 26 | 1.520 |
Why?
|
| Pneumoconiosis | 3 | 2021 | 3 | 1.490 |
Why?
|
| Lymph Node Excision | 9 | 2022 | 22 | 1.490 |
Why?
|
| Air Pollution | 6 | 2023 | 60 | 1.470 |
Why?
|
| Telemedicine | 5 | 2021 | 182 | 1.420 |
Why?
|
| Risk Factors | 35 | 2021 | 3562 | 1.420 |
Why?
|
| Time Factors | 23 | 2020 | 1742 | 1.400 |
Why?
|
| Hypothermia, Induced | 10 | 2020 | 26 | 1.330 |
Why?
|
| Kidney Calculi | 4 | 2018 | 6 | 1.290 |
Why?
|
| Cross-Sectional Studies | 24 | 2022 | 2721 | 1.260 |
Why?
|
| Vital Capacity | 8 | 2018 | 39 | 1.250 |
Why?
|
| Health Status | 7 | 2019 | 380 | 1.240 |
Why?
|
| Cost of Illness | 4 | 2017 | 76 | 1.230 |
Why?
|
| Lymph Nodes | 6 | 2021 | 67 | 1.220 |
Why?
|
| Respiratory Function Tests | 11 | 2020 | 55 | 1.210 |
Why?
|
| Kidney Failure, Chronic | 5 | 2020 | 233 | 1.160 |
Why?
|
| Emergency Service, Hospital | 3 | 2021 | 208 | 1.130 |
Why?
|
| Prospective Studies | 19 | 2023 | 1378 | 1.100 |
Why?
|
| Respiratory Tract Diseases | 3 | 2018 | 23 | 1.080 |
Why?
|
| Surgery, Computer-Assisted | 2 | 2016 | 4 | 1.070 |
Why?
|
| Coal Mining | 3 | 2021 | 7 | 1.020 |
Why?
|
| Adipokines | 4 | 2016 | 24 | 1.000 |
Why?
|
| Sputum | 3 | 2014 | 17 | 0.990 |
Why?
|
| Urinary Incontinence | 2 | 2022 | 15 | 0.980 |
Why?
|
| Salvage Therapy | 6 | 2023 | 10 | 0.970 |
Why?
|
| Smoke | 6 | 2023 | 40 | 0.960 |
Why?
|
| Hospitalization | 8 | 2020 | 388 | 0.960 |
Why?
|
| Follow-Up Studies | 17 | 2021 | 974 | 0.950 |
Why?
|
| Particulate Matter | 4 | 2023 | 51 | 0.940 |
Why?
|
| Databases, Factual | 15 | 2021 | 291 | 0.900 |
Why?
|
| Air Pollutants | 3 | 2023 | 94 | 0.880 |
Why?
|
| Forecasting | 2 | 2014 | 128 | 0.880 |
Why?
|
| Allergens | 3 | 2016 | 63 | 0.880 |
Why?
|
| Weight Gain | 2 | 2014 | 136 | 0.870 |
Why?
|
| Multivariate Analysis | 14 | 2019 | 583 | 0.850 |
Why?
|
| Quality of Life | 8 | 2022 | 481 | 0.840 |
Why?
|
| Incidence | 16 | 2023 | 922 | 0.840 |
Why?
|
| Penile Neoplasms | 1 | 2022 | 14 | 0.840 |
Why?
|
| Angina Pectoris | 3 | 2019 | 18 | 0.840 |
Why?
|
| Cohort Studies | 21 | 2024 | 1492 | 0.830 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 68 | 0.820 |
Why?
|
| Orchiectomy | 3 | 2016 | 35 | 0.820 |
Why?
|
| Tomography, X-Ray Computed | 11 | 2021 | 214 | 0.820 |
Why?
|
| Coal | 3 | 2021 | 10 | 0.810 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 76 | 0.810 |
Why?
|
| Healthcare Disparities | 6 | 2018 | 494 | 0.790 |
Why?
|
| Lung Neoplasms | 3 | 2022 | 358 | 0.790 |
Why?
|
| Lithotripsy | 1 | 2021 | 1 | 0.790 |
Why?
|
| Ureteral Neoplasms | 4 | 2024 | 4 | 0.790 |
Why?
|
| Carcinoma | 1 | 2022 | 96 | 0.780 |
Why?
|
| Length of Stay | 12 | 2023 | 185 | 0.780 |
Why?
|
| Fellowships and Scholarships | 2 | 2023 | 29 | 0.770 |
Why?
|
| Lymphatic Metastasis | 10 | 2024 | 65 | 0.760 |
Why?
|
| Sepsis | 3 | 2016 | 80 | 0.760 |
Why?
|
| Living Donors | 2 | 2017 | 15 | 0.750 |
Why?
|
| United States Indian Health Service | 1 | 2020 | 2 | 0.740 |
Why?
|
| Kidney | 3 | 2018 | 337 | 0.730 |
Why?
|
| Quality of Health Care | 4 | 2020 | 138 | 0.720 |
Why?
|
| Hospital Charges | 2 | 2017 | 13 | 0.720 |
Why?
|
| Overweight | 3 | 2022 | 247 | 0.720 |
Why?
|
| Home Care Services | 1 | 2020 | 33 | 0.720 |
Why?
|
| Blood Transfusion | 5 | 2015 | 27 | 0.720 |
Why?
|
| Young Adult | 27 | 2020 | 4268 | 0.710 |
Why?
|
| Patient Admission | 2 | 2017 | 41 | 0.710 |
Why?
|
| Adolescent | 27 | 2020 | 5363 | 0.700 |
Why?
|
| Survival Rate | 14 | 2024 | 311 | 0.700 |
Why?
|
| Leptin | 2 | 2012 | 118 | 0.700 |
Why?
|
| Faculty, Medical | 1 | 2020 | 66 | 0.690 |
Why?
|
| Nephrostomy, Percutaneous | 2 | 2016 | 3 | 0.680 |
Why?
|
| Biopsy | 3 | 2024 | 164 | 0.670 |
Why?
|
| Logistic Models | 13 | 2021 | 923 | 0.660 |
Why?
|
| Internet | 4 | 2020 | 211 | 0.660 |
Why?
|
| Urogenital Abnormalities | 1 | 2018 | 1 | 0.660 |
Why?
|
| Anus, Imperforate | 1 | 2018 | 2 | 0.660 |
Why?
|
| Pancreatic Diseases | 1 | 2018 | 5 | 0.650 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 2018 | 8 | 0.650 |
Why?
|
| Ectodermal Dysplasia | 1 | 2018 | 5 | 0.650 |
Why?
|
| Nose | 1 | 2018 | 15 | 0.650 |
Why?
|
| Urogenital Neoplasms | 1 | 2018 | 2 | 0.650 |
Why?
|
| Environmental Exposure | 5 | 2023 | 216 | 0.650 |
Why?
|
| Hypothyroidism | 1 | 2018 | 18 | 0.650 |
Why?
|
| Ultrasonography, Prenatal | 1 | 2018 | 33 | 0.640 |
Why?
|
| Neoplasm Staging | 17 | 2023 | 275 | 0.640 |
Why?
|
| Growth Disorders | 1 | 2018 | 22 | 0.640 |
Why?
|
| Community-Institutional Relations | 1 | 2020 | 187 | 0.640 |
Why?
|
| Neoplasm Invasiveness | 9 | 2024 | 251 | 0.640 |
Why?
|
| Urologic Diseases | 1 | 2018 | 2 | 0.640 |
Why?
|
| Testicular Hydrocele | 1 | 2018 | 1 | 0.640 |
Why?
|
| Early Detection of Cancer | 7 | 2023 | 336 | 0.640 |
Why?
|
| Scrotum | 1 | 2018 | 4 | 0.640 |
Why?
|
| Bronchial Hyperreactivity | 3 | 2008 | 12 | 0.640 |
Why?
|
| Pancreatitis | 1 | 2018 | 17 | 0.630 |
Why?
|
| Orthopedic Procedures | 2 | 2015 | 10 | 0.630 |
Why?
|
| Hotlines | 2 | 2008 | 14 | 0.620 |
Why?
|
| Gases | 1 | 2018 | 24 | 0.620 |
Why?
|
| Urinary Tract Infections | 2 | 2015 | 35 | 0.620 |
Why?
|
| Disease Progression | 8 | 2020 | 601 | 0.620 |
Why?
|
| Berylliosis | 2 | 2009 | 2 | 0.610 |
Why?
|
| Urinary Bladder, Neurogenic | 1 | 2017 | 3 | 0.610 |
Why?
|
| Indians, North American | 1 | 2020 | 159 | 0.610 |
Why?
|
| Adiposity | 2 | 2017 | 154 | 0.610 |
Why?
|
| Intraoperative Care | 2 | 2016 | 10 | 0.590 |
Why?
|
| Comorbidity | 9 | 2020 | 623 | 0.580 |
Why?
|
| Sex Factors | 6 | 2015 | 898 | 0.580 |
Why?
|
| Longitudinal Studies | 12 | 2021 | 885 | 0.580 |
Why?
|
| Inflammation Mediators | 3 | 2021 | 123 | 0.580 |
Why?
|
| Diabetes Mellitus | 1 | 2022 | 485 | 0.570 |
Why?
|
| Urology | 3 | 2023 | 7 | 0.570 |
Why?
|
| Spermatic Cord Torsion | 1 | 2016 | 2 | 0.570 |
Why?
|
| Aged, 80 and over | 21 | 2024 | 2379 | 0.560 |
Why?
|
| Frozen Sections | 1 | 2016 | 7 | 0.560 |
Why?
|
| Neoplasms | 6 | 2018 | 1103 | 0.560 |
Why?
|
| Prevalence | 6 | 2022 | 1455 | 0.550 |
Why?
|
| Mobile Health Units | 1 | 2016 | 7 | 0.540 |
Why?
|
| Adrenalectomy | 1 | 2015 | 25 | 0.540 |
Why?
|
| Inpatients | 3 | 2023 | 74 | 0.540 |
Why?
|
| Pancreatectomy | 2 | 2015 | 3 | 0.530 |
Why?
|
| Vena Cava, Inferior | 1 | 2015 | 7 | 0.530 |
Why?
|
| Preoperative Care | 2 | 2015 | 26 | 0.530 |
Why?
|
| Thrombectomy | 1 | 2015 | 13 | 0.520 |
Why?
|
| Mentors | 1 | 2016 | 127 | 0.520 |
Why?
|
| Oxidative Stress | 2 | 2013 | 938 | 0.520 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2015 | 23 | 0.520 |
Why?
|
| Hospitals, Pediatric | 1 | 2015 | 20 | 0.510 |
Why?
|
| Hypertension | 1 | 2022 | 796 | 0.510 |
Why?
|
| Expert Testimony | 1 | 2014 | 5 | 0.500 |
Why?
|
| Postoperative Hemorrhage | 1 | 2014 | 14 | 0.500 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2014 | 8 | 0.500 |
Why?
|
| Postoperative Care | 1 | 2014 | 18 | 0.490 |
Why?
|
| Spinal Fusion | 1 | 2014 | 12 | 0.490 |
Why?
|
| Ticlopidine | 1 | 2014 | 15 | 0.490 |
Why?
|
| Fibrinolytic Agents | 1 | 2014 | 25 | 0.490 |
Why?
|
| Adipose Tissue | 3 | 2011 | 177 | 0.490 |
Why?
|
| Hip Fractures | 1 | 2014 | 23 | 0.490 |
Why?
|
| Hemorrhage | 1 | 2014 | 45 | 0.490 |
Why?
|
| Lumbar Vertebrae | 1 | 2014 | 31 | 0.480 |
Why?
|
| Disability Evaluation | 1 | 2014 | 61 | 0.480 |
Why?
|
| Coronary Artery Bypass | 1 | 2014 | 43 | 0.480 |
Why?
|
| Aspirin | 1 | 2014 | 49 | 0.480 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2014 | 62 | 0.470 |
Why?
|
| Combined Modality Therapy | 4 | 2023 | 148 | 0.460 |
Why?
|
| Statistics as Topic | 1 | 2014 | 117 | 0.460 |
Why?
|
| Coronary Disease | 1 | 2014 | 124 | 0.450 |
Why?
|
| Prognosis | 12 | 2024 | 739 | 0.450 |
Why?
|
| Breath Tests | 1 | 2013 | 24 | 0.450 |
Why?
|
| Dinoprost | 1 | 2013 | 22 | 0.450 |
Why?
|
| Odds Ratio | 8 | 2020 | 534 | 0.440 |
Why?
|
| Developed Countries | 1 | 2012 | 12 | 0.440 |
Why?
|
| Bronchi | 1 | 2013 | 46 | 0.440 |
Why?
|
| Population Surveillance | 2 | 2019 | 238 | 0.440 |
Why?
|
| Ultrasonography | 3 | 2018 | 112 | 0.430 |
Why?
|
| DNA Methylation | 3 | 2014 | 325 | 0.430 |
Why?
|
| Genome-Wide Association Study | 5 | 2018 | 333 | 0.430 |
Why?
|
| Soot | 2 | 2023 | 4 | 0.430 |
Why?
|
| Patient Selection | 4 | 2018 | 164 | 0.430 |
Why?
|
| Androgen Antagonists | 4 | 2022 | 18 | 0.420 |
Why?
|
| Wood | 2 | 2022 | 16 | 0.420 |
Why?
|
| Liver | 1 | 2015 | 479 | 0.420 |
Why?
|
| Developing Countries | 1 | 2012 | 99 | 0.420 |
Why?
|
| BCG Vaccine | 3 | 2023 | 10 | 0.410 |
Why?
|
| Patient Readmission | 4 | 2018 | 73 | 0.410 |
Why?
|
| Smoking Cessation | 2 | 2009 | 517 | 0.410 |
Why?
|
| Dyspnea | 2 | 2022 | 18 | 0.400 |
Why?
|
| Demography | 3 | 2015 | 175 | 0.400 |
Why?
|
| Bronchial Provocation Tests | 2 | 2008 | 5 | 0.400 |
Why?
|
| Video Recording | 2 | 2010 | 32 | 0.400 |
Why?
|
| Child | 10 | 2022 | 3131 | 0.390 |
Why?
|
| Body Fat Distribution | 1 | 2011 | 24 | 0.380 |
Why?
|
| Registries | 4 | 2017 | 335 | 0.370 |
Why?
|
| Alveolitis, Extrinsic Allergic | 2 | 2006 | 2 | 0.360 |
Why?
|
| Animals | 15 | 2024 | 15081 | 0.350 |
Why?
|
| Age Factors | 9 | 2020 | 1033 | 0.350 |
Why?
|
| Rest | 1 | 2009 | 26 | 0.350 |
Why?
|
| Respiratory Mechanics | 1 | 2009 | 27 | 0.350 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2009 | 53 | 0.350 |
Why?
|
| Linear Models | 5 | 2017 | 275 | 0.340 |
Why?
|
| Survival Analysis | 5 | 2022 | 325 | 0.340 |
Why?
|
| Recurrence | 3 | 2023 | 131 | 0.340 |
Why?
|
| Vehicle Emissions | 2 | 2021 | 23 | 0.340 |
Why?
|
| Telephone | 1 | 2009 | 34 | 0.340 |
Why?
|
| Health Services Accessibility | 3 | 2020 | 560 | 0.330 |
Why?
|
| Patient Education as Topic | 1 | 2010 | 215 | 0.330 |
Why?
|
| Child, Preschool | 8 | 2016 | 1418 | 0.330 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 2 | 2022 | 69 | 0.320 |
Why?
|
| Urologic Neoplasms | 3 | 2024 | 4 | 0.320 |
Why?
|
| Predictive Value of Tests | 5 | 2017 | 400 | 0.320 |
Why?
|
| Bronchoalveolar Lavage Fluid | 2 | 2016 | 56 | 0.320 |
Why?
|
| Case-Control Studies | 6 | 2016 | 1130 | 0.320 |
Why?
|
| Phenotype | 4 | 2013 | 689 | 0.320 |
Why?
|
| Burns, Chemical | 1 | 2007 | 4 | 0.310 |
Why?
|
| Abdominal Pain | 2 | 2018 | 24 | 0.310 |
Why?
|
| Ammonia | 1 | 2007 | 17 | 0.310 |
Why?
|
| Adenocarcinoma | 2 | 2020 | 251 | 0.310 |
Why?
|
| Counseling | 1 | 2009 | 116 | 0.310 |
Why?
|
| Diagnosis, Differential | 2 | 2018 | 217 | 0.310 |
Why?
|
| Referral and Consultation | 2 | 2020 | 117 | 0.300 |
Why?
|
| Metals | 2 | 2018 | 98 | 0.300 |
Why?
|
| Exercise | 2 | 2011 | 613 | 0.290 |
Why?
|
| Mycobacterium avium Complex | 1 | 2006 | 2 | 0.290 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 2006 | 18 | 0.290 |
Why?
|
| Immunoenzyme Techniques | 1 | 2006 | 108 | 0.280 |
Why?
|
| Granuloma | 1 | 2006 | 26 | 0.280 |
Why?
|
| Seminal Vesicles | 3 | 2021 | 9 | 0.280 |
Why?
|
| Data Interpretation, Statistical | 1 | 2007 | 111 | 0.280 |
Why?
|
| Pulmonary Fibrosis | 2 | 2021 | 31 | 0.280 |
Why?
|
| Vulnerable Populations | 1 | 2008 | 140 | 0.280 |
Why?
|
| Inhalation Exposure | 3 | 2021 | 43 | 0.280 |
Why?
|
| Water Microbiology | 1 | 2006 | 76 | 0.270 |
Why?
|
| Recovery of Function | 3 | 2022 | 88 | 0.270 |
Why?
|
| Proportional Hazards Models | 9 | 2017 | 441 | 0.270 |
Why?
|
| Positron-Emission Tomography | 2 | 2023 | 80 | 0.270 |
Why?
|
| Cardiovascular Diseases | 4 | 2019 | 664 | 0.270 |
Why?
|
| Hot Temperature | 1 | 2006 | 128 | 0.270 |
Why?
|
| Intra-Abdominal Fat | 2 | 2017 | 45 | 0.270 |
Why?
|
| Rural Population | 2 | 2020 | 294 | 0.270 |
Why?
|
| Urologic Surgical Procedures | 2 | 2016 | 5 | 0.270 |
Why?
|
| Nomograms | 2 | 2016 | 9 | 0.270 |
Why?
|
| Central Nervous System Stimulants | 1 | 2007 | 174 | 0.260 |
Why?
|
| Methamphetamine | 1 | 2007 | 159 | 0.260 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2006 | 90 | 0.260 |
Why?
|
| SEER Program | 5 | 2016 | 91 | 0.260 |
Why?
|
| Severity of Illness Index | 5 | 2018 | 610 | 0.260 |
Why?
|
| Nutrition Surveys | 1 | 2007 | 242 | 0.260 |
Why?
|
| Hormone Replacement Therapy | 2 | 2022 | 41 | 0.260 |
Why?
|
| Radiotherapy | 4 | 2017 | 18 | 0.250 |
Why?
|
| Bone Neoplasms | 2 | 2016 | 45 | 0.250 |
Why?
|
| Attitude to Health | 1 | 2008 | 325 | 0.250 |
Why?
|
| Administration, Inhalation | 3 | 2023 | 80 | 0.250 |
Why?
|
| Mass Screening | 4 | 2023 | 462 | 0.250 |
Why?
|
| Glucocorticoids | 1 | 2004 | 86 | 0.240 |
Why?
|
| Kidney Pelvis | 2 | 2014 | 4 | 0.240 |
Why?
|
| Risk-Taking | 1 | 2008 | 451 | 0.240 |
Why?
|
| Dust | 2 | 2021 | 54 | 0.240 |
Why?
|
| Societies, Medical | 4 | 2019 | 66 | 0.240 |
Why?
|
| Ureteral Obstruction | 2 | 2014 | 17 | 0.240 |
Why?
|
| Cystitis | 1 | 2023 | 8 | 0.240 |
Why?
|
| Genetic Loci | 2 | 2014 | 90 | 0.240 |
Why?
|
| Disease-Free Survival | 7 | 2017 | 113 | 0.230 |
Why?
|
| Health Behavior | 1 | 2008 | 537 | 0.230 |
Why?
|
| Eosinophilia | 1 | 2023 | 18 | 0.230 |
Why?
|
| Risk | 2 | 2017 | 267 | 0.220 |
Why?
|
| Erectile Dysfunction | 1 | 2023 | 38 | 0.220 |
Why?
|
| Preventive Health Services | 2 | 2017 | 64 | 0.220 |
Why?
|
| Pelvis | 3 | 2017 | 14 | 0.220 |
Why?
|
| Infant | 6 | 2016 | 1046 | 0.220 |
Why?
|
| Artificial Intelligence | 1 | 2023 | 70 | 0.220 |
Why?
|
| Neoplasms, Second Primary | 1 | 2022 | 13 | 0.220 |
Why?
|
| GATA4 Transcription Factor | 2 | 2014 | 6 | 0.220 |
Why?
|
| Menopause, Premature | 1 | 2022 | 5 | 0.220 |
Why?
|
| Inguinal Canal | 1 | 2022 | 4 | 0.210 |
Why?
|
| Radiosurgery | 1 | 2022 | 51 | 0.210 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2022 | 37 | 0.210 |
Why?
|
| Sex Distribution | 2 | 2020 | 215 | 0.210 |
Why?
|
| Endocrine System Diseases | 2 | 2018 | 13 | 0.200 |
Why?
|
| Coronary Artery Disease | 2 | 2015 | 142 | 0.200 |
Why?
|
| Chi-Square Distribution | 3 | 2017 | 225 | 0.200 |
Why?
|
| North America | 4 | 2024 | 67 | 0.200 |
Why?
|
| Promoter Regions, Genetic | 3 | 2019 | 515 | 0.200 |
Why?
|
| Internship and Residency | 1 | 2023 | 125 | 0.200 |
Why?
|
| Surgical Wound Infection | 3 | 2018 | 16 | 0.200 |
Why?
|
| Sexual Dysfunction, Physiological | 2 | 2018 | 14 | 0.200 |
Why?
|
| Airway Remodeling | 2 | 2018 | 11 | 0.200 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2021 | 24 | 0.200 |
Why?
|
| Depression | 2 | 2021 | 712 | 0.200 |
Why?
|
| Inflammation | 3 | 2015 | 618 | 0.200 |
Why?
|
| Social Class | 2 | 2017 | 247 | 0.200 |
Why?
|
| Nails | 1 | 2020 | 5 | 0.190 |
Why?
|
| Antineoplastic Agents, Hormonal | 3 | 2017 | 33 | 0.190 |
Why?
|
| Anastomosis, Surgical | 3 | 2018 | 21 | 0.190 |
Why?
|
| Hypogonadism | 1 | 2020 | 21 | 0.190 |
Why?
|
| Warm Ischemia | 3 | 2015 | 3 | 0.190 |
Why?
|
| Home Health Aides | 1 | 2020 | 1 | 0.190 |
Why?
|
| Chronic Disease | 3 | 2017 | 484 | 0.180 |
Why?
|
| Feasibility Studies | 3 | 2016 | 208 | 0.180 |
Why?
|
| Interdisciplinary Communication | 1 | 2020 | 36 | 0.180 |
Why?
|
| Critical Pathways | 1 | 2020 | 15 | 0.180 |
Why?
|
| Cost-Benefit Analysis | 1 | 2021 | 144 | 0.180 |
Why?
|
| Opioid-Related Disorders | 1 | 2023 | 125 | 0.180 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2022 | 268 | 0.180 |
Why?
|
| Pulmonary Emphysema | 1 | 2020 | 12 | 0.180 |
Why?
|
| Microphthalmia-Associated Transcription Factor | 1 | 2019 | 2 | 0.180 |
Why?
|
| Infant, Newborn | 3 | 2018 | 894 | 0.180 |
Why?
|
| Education, Medical, Continuing | 1 | 2020 | 32 | 0.180 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2023 | 182 | 0.180 |
Why?
|
| Iron | 1 | 2021 | 225 | 0.170 |
Why?
|
| Zinc | 1 | 2020 | 128 | 0.170 |
Why?
|
| Academic Medical Centers | 1 | 2020 | 60 | 0.170 |
Why?
|
| Environmental Health | 1 | 2019 | 41 | 0.170 |
Why?
|
| Hospital Mortality | 3 | 2016 | 187 | 0.170 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2019 | 20 | 0.170 |
Why?
|
| Lysosomes | 1 | 2019 | 91 | 0.170 |
Why?
|
| Chemotherapy, Adjuvant | 4 | 2024 | 37 | 0.170 |
Why?
|
| Health Status Disparities | 2 | 2016 | 642 | 0.170 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2019 | 22 | 0.170 |
Why?
|
| Pancreaticoduodenectomy | 1 | 2018 | 3 | 0.170 |
Why?
|
| Muscles | 1 | 2019 | 82 | 0.170 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2018 | 12 | 0.170 |
Why?
|
| Hypothermia | 1 | 2018 | 11 | 0.170 |
Why?
|
| Multicenter Studies as Topic | 1 | 2018 | 41 | 0.170 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 1 | 2018 | 12 | 0.160 |
Why?
|
| Heating | 1 | 2018 | 4 | 0.160 |
Why?
|
| Enteral Nutrition | 1 | 2018 | 16 | 0.160 |
Why?
|
| Rural Health | 1 | 2019 | 53 | 0.160 |
Why?
|
| Primary Health Care | 1 | 2021 | 294 | 0.160 |
Why?
|
| Libido | 1 | 2018 | 6 | 0.160 |
Why?
|
| Pamphlets | 1 | 2018 | 26 | 0.160 |
Why?
|
| Penile Erection | 1 | 2018 | 26 | 0.160 |
Why?
|
| Urography | 1 | 2018 | 1 | 0.160 |
Why?
|
| Myocardial Infarction | 3 | 2016 | 225 | 0.160 |
Why?
|
| Cadaver | 2 | 2015 | 42 | 0.160 |
Why?
|
| Sexual Dysfunctions, Psychological | 1 | 2018 | 13 | 0.160 |
Why?
|
| Cough | 1 | 2018 | 18 | 0.160 |
Why?
|
| Activities of Daily Living | 2 | 2016 | 105 | 0.160 |
Why?
|
| Infertility | 1 | 2018 | 18 | 0.160 |
Why?
|
| Household Products | 1 | 2018 | 2 | 0.160 |
Why?
|
| Radiotherapy, Adjuvant | 4 | 2020 | 16 | 0.160 |
Why?
|
| Posture | 1 | 2018 | 58 | 0.160 |
Why?
|
| Macrophages, Alveolar | 1 | 2018 | 34 | 0.160 |
Why?
|
| Creatinine | 2 | 2018 | 103 | 0.150 |
Why?
|
| Decision Support Techniques | 1 | 2018 | 47 | 0.150 |
Why?
|
| Health Status Indicators | 2 | 2018 | 75 | 0.150 |
Why?
|
| Sensitivity and Specificity | 3 | 2009 | 562 | 0.150 |
Why?
|
| Acute Disease | 1 | 2018 | 147 | 0.150 |
Why?
|
| Illinois | 2 | 2008 | 9 | 0.150 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2019 | 269 | 0.150 |
Why?
|
| Magnetic Resonance Imaging, Interventional | 1 | 2017 | 1 | 0.150 |
Why?
|
| Mortality | 1 | 2018 | 145 | 0.150 |
Why?
|
| Keratinocytes | 1 | 2017 | 66 | 0.150 |
Why?
|
| Minority Groups | 1 | 2022 | 596 | 0.150 |
Why?
|
| Anesthesia, Epidural | 1 | 2016 | 3 | 0.150 |
Why?
|
| Anesthesia, General | 1 | 2016 | 9 | 0.150 |
Why?
|
| Hypoalbuminemia | 1 | 2016 | 4 | 0.150 |
Why?
|
| Anthropometry | 1 | 2017 | 97 | 0.150 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 2016 | 17 | 0.140 |
Why?
|
| Hypersensitivity, Immediate | 1 | 2016 | 11 | 0.140 |
Why?
|
| Markov Chains | 1 | 2016 | 35 | 0.140 |
Why?
|
| Mediastinal Neoplasms | 1 | 2016 | 6 | 0.140 |
Why?
|
| Intestines | 1 | 2016 | 64 | 0.140 |
Why?
|
| Antibodies, Monoclonal | 1 | 2018 | 290 | 0.140 |
Why?
|
| Patient Discharge | 1 | 2017 | 93 | 0.140 |
Why?
|
| Meta-Analysis as Topic | 2 | 2014 | 30 | 0.140 |
Why?
|
| Regression Analysis | 3 | 2015 | 455 | 0.140 |
Why?
|
| Ischemia | 1 | 2016 | 46 | 0.140 |
Why?
|
| Practice Guidelines as Topic | 3 | 2017 | 191 | 0.140 |
Why?
|
| Genome, Human | 2 | 2014 | 135 | 0.140 |
Why?
|
| PTEN Phosphohydrolase | 2 | 2013 | 54 | 0.140 |
Why?
|
| Infrared Rays | 1 | 2016 | 18 | 0.140 |
Why?
|
| Physical Examination | 1 | 2016 | 43 | 0.140 |
Why?
|
| Faculty | 1 | 2016 | 94 | 0.130 |
Why?
|
| Specimen Handling | 1 | 2016 | 56 | 0.130 |
Why?
|
| Radiography | 1 | 2016 | 72 | 0.130 |
Why?
|
| Fluorescence | 1 | 2016 | 121 | 0.130 |
Why?
|
| Peritoneum | 1 | 2015 | 8 | 0.130 |
Why?
|
| Hypospadias | 1 | 2015 | 3 | 0.130 |
Why?
|
| Obesity, Morbid | 1 | 2015 | 23 | 0.130 |
Why?
|
| Diaphragm | 1 | 2015 | 11 | 0.130 |
Why?
|
| Kallikreins | 1 | 2015 | 9 | 0.130 |
Why?
|
| Medicine | 1 | 2015 | 33 | 0.130 |
Why?
|
| Swine | 1 | 2016 | 184 | 0.130 |
Why?
|
| Transplantation, Autologous | 1 | 2015 | 8 | 0.130 |
Why?
|
| Gonadotropin-Releasing Hormone | 1 | 2015 | 33 | 0.130 |
Why?
|
| Cardiovascular Surgical Procedures | 1 | 2015 | 5 | 0.130 |
Why?
|
| Research Personnel | 1 | 2016 | 155 | 0.130 |
Why?
|
| Growth Substances | 1 | 2015 | 14 | 0.130 |
Why?
|
| Lectins | 1 | 2015 | 20 | 0.130 |
Why?
|
| Nocturia | 1 | 2015 | 1 | 0.130 |
Why?
|
| Cardiopulmonary Resuscitation | 2 | 2015 | 23 | 0.130 |
Why?
|
| Patient Satisfaction | 1 | 2016 | 145 | 0.130 |
Why?
|
| Urolithiasis | 1 | 2015 | 2 | 0.130 |
Why?
|
| Th2 Cells | 1 | 2015 | 58 | 0.130 |
Why?
|
| Insurance Coverage | 1 | 2015 | 100 | 0.130 |
Why?
|
| Fluid Therapy | 1 | 2015 | 28 | 0.130 |
Why?
|
| Terminal Care | 1 | 2015 | 45 | 0.130 |
Why?
|
| Delivery of Health Care | 1 | 2018 | 276 | 0.130 |
Why?
|
| Eligibility Determination | 1 | 2014 | 6 | 0.130 |
Why?
|
| Hospice Care | 1 | 2015 | 15 | 0.130 |
Why?
|
| India | 1 | 2015 | 88 | 0.130 |
Why?
|
| Biological Assay | 1 | 2015 | 59 | 0.120 |
Why?
|
| Sleep Apnea Syndromes | 1 | 2015 | 29 | 0.120 |
Why?
|
| Graft Survival | 1 | 2015 | 39 | 0.120 |
Why?
|
| Neoplasm Metastasis | 4 | 2016 | 219 | 0.120 |
Why?
|
| Insurance, Health | 1 | 2015 | 126 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2014 | 15 | 0.120 |
Why?
|
| Neoplasm Proteins | 1 | 2016 | 213 | 0.120 |
Why?
|
| Immunosuppressive Agents | 1 | 2015 | 76 | 0.120 |
Why?
|
| Physician-Patient Relations | 1 | 2015 | 128 | 0.120 |
Why?
|
| Transurethral Resection of Prostate | 1 | 2014 | 2 | 0.120 |
Why?
|
| Cold Ischemia | 1 | 2014 | 1 | 0.120 |
Why?
|
| Time and Motion Studies | 1 | 2014 | 9 | 0.120 |
Why?
|
| gamma-Tocopherol | 1 | 2014 | 19 | 0.120 |
Why?
|
| Ureter | 1 | 2014 | 7 | 0.120 |
Why?
|
| Hyperthermia, Induced | 1 | 2014 | 17 | 0.120 |
Why?
|
| Biomedical Research | 2 | 2016 | 400 | 0.120 |
Why?
|
| alpha-Tocopherol | 1 | 2014 | 27 | 0.120 |
Why?
|
| Quality Control | 1 | 2014 | 36 | 0.120 |
Why?
|
| Carcinoma, Acinar Cell | 1 | 2013 | 1 | 0.120 |
Why?
|
| Heart Diseases | 1 | 2015 | 104 | 0.120 |
Why?
|
| Carcinoma, Small Cell | 1 | 2013 | 6 | 0.120 |
Why?
|
| Respiration | 1 | 2014 | 58 | 0.120 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2013 | 4 | 0.120 |
Why?
|
| Signal Transduction | 3 | 2019 | 1908 | 0.120 |
Why?
|
| Laser Therapy | 1 | 2014 | 30 | 0.120 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2017 | 481 | 0.120 |
Why?
|
| Retinoblastoma Protein | 1 | 2013 | 27 | 0.120 |
Why?
|
| Prostatic Hyperplasia | 1 | 2014 | 34 | 0.120 |
Why?
|
| Biosensing Techniques | 1 | 2015 | 86 | 0.120 |
Why?
|
| Bronchodilator Agents | 2 | 2023 | 25 | 0.120 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2015 | 92 | 0.110 |
Why?
|
| Intercellular Adhesion Molecule-1 | 2 | 2015 | 56 | 0.110 |
Why?
|
| Glomerular Filtration Rate | 1 | 2014 | 139 | 0.110 |
Why?
|
| Radioimmunoassay | 1 | 2013 | 65 | 0.110 |
Why?
|
| Self Care | 2 | 2019 | 159 | 0.110 |
Why?
|
| Administration, Intravesical | 2 | 2023 | 5 | 0.110 |
Why?
|
| Age of Onset | 1 | 2013 | 100 | 0.110 |
Why?
|
| Pregnancy | 1 | 2018 | 1549 | 0.110 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2012 | 36 | 0.110 |
Why?
|
| Cytokines | 1 | 2016 | 602 | 0.110 |
Why?
|
| Sex Characteristics | 2 | 2015 | 230 | 0.110 |
Why?
|
| Research Design | 3 | 2019 | 313 | 0.110 |
Why?
|
| Critical Illness | 1 | 2012 | 38 | 0.100 |
Why?
|
| Endothelial Cells | 1 | 2015 | 308 | 0.100 |
Why?
|
| Leukocyte Count | 2 | 2021 | 77 | 0.100 |
Why?
|
| Analysis of Variance | 2 | 2014 | 550 | 0.100 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2013 | 448 | 0.100 |
Why?
|
| Exercise Test | 1 | 2011 | 67 | 0.100 |
Why?
|
| Antineoplastic Agents | 1 | 2018 | 803 | 0.100 |
Why?
|
| Urinary Bladder | 2 | 2024 | 29 | 0.100 |
Why?
|
| Disease Models, Animal | 1 | 2016 | 1371 | 0.090 |
Why?
|
| Physical Fitness | 1 | 2011 | 90 | 0.090 |
Why?
|
| Genes, p16 | 1 | 2010 | 9 | 0.090 |
Why?
|
| Receptor, erbB-2 | 2 | 2024 | 133 | 0.090 |
Why?
|
| New Zealand | 1 | 2010 | 21 | 0.090 |
Why?
|
| Sample Size | 1 | 2010 | 25 | 0.090 |
Why?
|
| Body Composition | 1 | 2011 | 162 | 0.090 |
Why?
|
| China | 2 | 2021 | 196 | 0.090 |
Why?
|
| Absorptiometry, Photon | 1 | 2010 | 75 | 0.090 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2010 | 19 | 0.090 |
Why?
|
| Epigenesis, Genetic | 1 | 2012 | 219 | 0.090 |
Why?
|
| Life Expectancy | 2 | 2023 | 42 | 0.090 |
Why?
|
| Fasting | 1 | 2010 | 54 | 0.090 |
Why?
|
| Pulmonary Ventilation | 1 | 2009 | 4 | 0.090 |
Why?
|
| Respiratory Muscles | 1 | 2009 | 10 | 0.090 |
Why?
|
| Information Dissemination | 1 | 2010 | 59 | 0.090 |
Why?
|
| Polymorphism, Single Nucleotide | 4 | 2017 | 767 | 0.090 |
Why?
|
| F2-Isoprostanes | 1 | 2009 | 20 | 0.090 |
Why?
|
| Urothelium | 1 | 2009 | 8 | 0.090 |
Why?
|
| P-Selectin | 1 | 2009 | 7 | 0.090 |
Why?
|
| Oxygen Consumption | 1 | 2009 | 103 | 0.080 |
Why?
|
| Cholesterol, LDL | 1 | 2009 | 68 | 0.080 |
Why?
|
| Age Distribution | 3 | 2015 | 225 | 0.080 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2008 | 24 | 0.080 |
Why?
|
| Influenza, Human | 1 | 2010 | 83 | 0.080 |
Why?
|
| Cells, Cultured | 3 | 2019 | 1518 | 0.080 |
Why?
|
| Gene Expression Regulation | 1 | 2014 | 1015 | 0.080 |
Why?
|
| Socioeconomic Factors | 2 | 2015 | 1067 | 0.080 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2015 | 864 | 0.080 |
Why?
|
| Probability | 1 | 2008 | 78 | 0.080 |
Why?
|
| Reference Values | 1 | 2008 | 212 | 0.080 |
Why?
|
| Body Temperature | 2 | 2021 | 36 | 0.080 |
Why?
|
| Burns, Inhalation | 1 | 2007 | 1 | 0.080 |
Why?
|
| Eye Burns | 1 | 2007 | 3 | 0.080 |
Why?
|
| Iowa | 1 | 2008 | 8 | 0.080 |
Why?
|
| Stem Cells | 1 | 2009 | 141 | 0.080 |
Why?
|
| Accidents, Occupational | 1 | 2007 | 7 | 0.080 |
Why?
|
| Clinical Trials as Topic | 2 | 2020 | 204 | 0.080 |
Why?
|
| Algorithms | 2 | 2023 | 465 | 0.080 |
Why?
|
| Decision Making | 2 | 2023 | 203 | 0.080 |
Why?
|
| Premenopause | 1 | 2008 | 104 | 0.080 |
Why?
|
| Health Care Surveys | 1 | 2008 | 136 | 0.080 |
Why?
|
| Agriculture | 1 | 2007 | 56 | 0.070 |
Why?
|
| Educational Status | 1 | 2009 | 313 | 0.070 |
Why?
|
| Reference Standards | 1 | 2007 | 52 | 0.070 |
Why?
|
| Methacholine Chloride | 1 | 2006 | 2 | 0.070 |
Why?
|
| Aerosols | 1 | 2006 | 48 | 0.070 |
Why?
|
| Brachytherapy | 2 | 2016 | 7 | 0.070 |
Why?
|
| Reoperation | 2 | 2016 | 24 | 0.070 |
Why?
|
| Industrial Oils | 1 | 2005 | 1 | 0.070 |
Why?
|
| Metallurgy | 1 | 2005 | 1 | 0.070 |
Why?
|
| Respiratory System | 1 | 2005 | 28 | 0.060 |
Why?
|
| Pulmonary Diffusing Capacity | 1 | 2004 | 5 | 0.060 |
Why?
|
| Colectomy | 2 | 2015 | 16 | 0.060 |
Why?
|
| Cystoscopy | 2 | 2015 | 4 | 0.060 |
Why?
|
| Hysterectomy | 2 | 2015 | 28 | 0.060 |
Why?
|
| Poverty | 1 | 2008 | 348 | 0.060 |
Why?
|
| Antigens, CD | 2 | 2019 | 121 | 0.060 |
Why?
|
| Lymphatic Vessels | 1 | 2024 | 6 | 0.060 |
Why?
|
| Hospitals, Teaching | 1 | 2023 | 27 | 0.060 |
Why?
|
| Nebulizers and Vaporizers | 1 | 2023 | 19 | 0.060 |
Why?
|
| Hospital Costs | 1 | 2023 | 24 | 0.060 |
Why?
|
| Mice | 4 | 2019 | 5913 | 0.060 |
Why?
|
| Cisplatin | 1 | 2024 | 72 | 0.060 |
Why?
|
| Men | 1 | 2023 | 19 | 0.060 |
Why?
|
| Taxoids | 1 | 2023 | 37 | 0.060 |
Why?
|
| Particle Size | 1 | 2023 | 215 | 0.050 |
Why?
|
| Adjuvants, Immunologic | 1 | 2023 | 107 | 0.050 |
Why?
|
| Immunohistochemistry | 2 | 2019 | 893 | 0.050 |
Why?
|
| Carbon | 1 | 2023 | 105 | 0.050 |
Why?
|
| Menopause | 1 | 2022 | 56 | 0.050 |
Why?
|
| Cell Differentiation | 2 | 2017 | 587 | 0.050 |
Why?
|
| Androgens | 1 | 2022 | 89 | 0.050 |
Why?
|
| Choline | 1 | 2022 | 59 | 0.050 |
Why?
|
| Genomics | 1 | 2024 | 223 | 0.050 |
Why?
|
| Biomedical Technology | 1 | 2021 | 8 | 0.050 |
Why?
|
| Tumor Burden | 1 | 2021 | 77 | 0.050 |
Why?
|
| Schools, Medical | 1 | 2023 | 198 | 0.050 |
Why?
|
| Infection Control | 1 | 2021 | 14 | 0.050 |
Why?
|
| Analgesics, Opioid | 1 | 2023 | 197 | 0.050 |
Why?
|
| Occupational Health | 1 | 2021 | 29 | 0.050 |
Why?
|
| Carcinoma, Adenosquamous | 1 | 2020 | 4 | 0.050 |
Why?
|
| Carcinoma, Signet Ring Cell | 1 | 2020 | 4 | 0.050 |
Why?
|
| Carcinosarcoma | 1 | 2020 | 4 | 0.050 |
Why?
|
| Carcinoma, Ductal | 1 | 2020 | 4 | 0.050 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2020 | 16 | 0.050 |
Why?
|
| Triage | 1 | 2020 | 26 | 0.050 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2019 | 9 | 0.040 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2019 | 17 | 0.040 |
Why?
|
| Macrophages | 1 | 2023 | 439 | 0.040 |
Why?
|
| Radiology | 1 | 2019 | 10 | 0.040 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2019 | 59 | 0.040 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2023 | 404 | 0.040 |
Why?
|
| Testosterone | 1 | 2020 | 193 | 0.040 |
Why?
|
| Climate Change | 1 | 2019 | 35 | 0.040 |
Why?
|
| Family | 1 | 2020 | 173 | 0.040 |
Why?
|
| Drug Administration Schedule | 1 | 2019 | 143 | 0.040 |
Why?
|
| Unnecessary Procedures | 1 | 2018 | 9 | 0.040 |
Why?
|
| Digestive System Diseases | 1 | 2018 | 4 | 0.040 |
Why?
|
| Mutation | 1 | 2024 | 1095 | 0.040 |
Why?
|
| Gastric Emptying | 1 | 2018 | 13 | 0.040 |
Why?
|
| Bone Diseases | 1 | 2018 | 18 | 0.040 |
Why?
|
| Immune System Diseases | 1 | 2018 | 21 | 0.040 |
Why?
|
| Skin Diseases | 1 | 2018 | 31 | 0.040 |
Why?
|
| Uteroglobin | 1 | 2018 | 8 | 0.040 |
Why?
|
| Health Policy | 1 | 2019 | 165 | 0.040 |
Why?
|
| Urination Disorders | 1 | 2017 | 3 | 0.040 |
Why?
|
| Cancer Care Facilities | 1 | 2018 | 17 | 0.040 |
Why?
|
| Nervous System Diseases | 1 | 2018 | 71 | 0.040 |
Why?
|
| Desmosomes | 1 | 2017 | 1 | 0.040 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2017 | 24 | 0.040 |
Why?
|
| Advisory Committees | 1 | 2017 | 29 | 0.040 |
Why?
|
| rho-Associated Kinases | 1 | 2017 | 31 | 0.040 |
Why?
|
| Aging | 1 | 2022 | 664 | 0.040 |
Why?
|
| Back Pain | 1 | 2017 | 19 | 0.040 |
Why?
|
| Incontinence Pads | 1 | 2017 | 3 | 0.040 |
Why?
|
| Urinary Catheterization | 1 | 2017 | 4 | 0.040 |
Why?
|
| Michigan | 1 | 2017 | 22 | 0.040 |
Why?
|
| Device Removal | 1 | 2017 | 6 | 0.040 |
Why?
|
| Osteoarthritis | 1 | 2017 | 20 | 0.040 |
Why?
|
| Europe | 1 | 2017 | 101 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2020 | 935 | 0.040 |
Why?
|
| Travel | 1 | 2017 | 32 | 0.040 |
Why?
|
| Surgical Wound Dehiscence | 1 | 2016 | 7 | 0.040 |
Why?
|
| Mediastinum | 1 | 2016 | 5 | 0.040 |
Why?
|
| Respiratory Hypersensitivity | 1 | 2016 | 16 | 0.040 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2016 | 11 | 0.040 |
Why?
|
| Cell Adhesion | 1 | 2017 | 212 | 0.040 |
Why?
|
| Stents | 1 | 2016 | 59 | 0.030 |
Why?
|
| Cross-Over Studies | 1 | 2016 | 108 | 0.030 |
Why?
|
| Enzyme Activation | 1 | 2017 | 444 | 0.030 |
Why?
|
| Transforming Growth Factor beta | 1 | 2017 | 197 | 0.030 |
Why?
|
| Neoplasm, Residual | 1 | 2015 | 13 | 0.030 |
Why?
|
| Venous Thromboembolism | 1 | 2015 | 13 | 0.030 |
Why?
|
| Office Visits | 1 | 2015 | 22 | 0.030 |
Why?
|
| Health Care Costs | 1 | 2016 | 77 | 0.030 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2015 | 26 | 0.030 |
Why?
|
| Workload | 1 | 2015 | 22 | 0.030 |
Why?
|
| Renal Dialysis | 1 | 2016 | 120 | 0.030 |
Why?
|
| Medically Uninsured | 1 | 2015 | 56 | 0.030 |
Why?
|
| Critical Care | 1 | 2015 | 41 | 0.030 |
Why?
|
| Perioperative Care | 1 | 2015 | 6 | 0.030 |
Why?
|
| Gastrectomy | 1 | 2015 | 10 | 0.030 |
Why?
|
| Esophagectomy | 1 | 2015 | 6 | 0.030 |
Why?
|
| Pneumonectomy | 1 | 2015 | 7 | 0.030 |
Why?
|
| Preoperative Period | 1 | 2015 | 7 | 0.030 |
Why?
|
| Luminescent Measurements | 1 | 2015 | 26 | 0.030 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2015 | 28 | 0.030 |
Why?
|
| Interleukin-8 | 1 | 2015 | 60 | 0.030 |
Why?
|
| Appendectomy | 1 | 2014 | 16 | 0.030 |
Why?
|
| Propensity Score | 1 | 2014 | 38 | 0.030 |
Why?
|
| Hospitals | 1 | 2015 | 86 | 0.030 |
Why?
|
| Coronary Vessels | 1 | 2015 | 85 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2017 | 933 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2014 | 64 | 0.030 |
Why?
|
| Patient Positioning | 1 | 2014 | 4 | 0.030 |
Why?
|
| Medicaid | 1 | 2015 | 109 | 0.030 |
Why?
|
| Hematocrit | 1 | 2014 | 18 | 0.030 |
Why?
|
| Veterans | 1 | 2015 | 122 | 0.030 |
Why?
|
| Intraoperative Complications | 1 | 2014 | 18 | 0.030 |
Why?
|
| Quantitative Trait Loci | 1 | 2014 | 77 | 0.030 |
Why?
|
| Databases, Genetic | 1 | 2014 | 93 | 0.030 |
Why?
|
| Morbidity | 1 | 2014 | 91 | 0.030 |
Why?
|
| Medicare | 1 | 2015 | 195 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2016 | 661 | 0.030 |
Why?
|
| Serum Albumin | 1 | 2014 | 50 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2013 | 93 | 0.030 |
Why?
|
| Vitamin E | 1 | 2014 | 61 | 0.030 |
Why?
|
| Gene Dosage | 1 | 2013 | 75 | 0.030 |
Why?
|
| Guidelines as Topic | 1 | 2013 | 54 | 0.030 |
Why?
|
| Mammary Glands, Animal | 1 | 2013 | 26 | 0.030 |
Why?
|
| Feedback, Physiological | 1 | 2013 | 31 | 0.030 |
Why?
|
| Physicians | 1 | 2015 | 163 | 0.030 |
Why?
|
| src-Family Kinases | 1 | 2013 | 46 | 0.030 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2013 | 59 | 0.030 |
Why?
|
| Epithelium | 1 | 2013 | 79 | 0.030 |
Why?
|
| HLA-DQ Antigens | 1 | 2012 | 6 | 0.030 |
Why?
|
| Gene Deletion | 1 | 2013 | 166 | 0.030 |
Why?
|
| SOX9 Transcription Factor | 1 | 2012 | 10 | 0.030 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2013 | 84 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2017 | 1609 | 0.030 |
Why?
|
| Cell Culture Techniques | 1 | 2013 | 142 | 0.030 |
Why?
|
| Fishes | 1 | 2012 | 53 | 0.030 |
Why?
|
| Potassium Channels, Inwardly Rectifying | 1 | 2012 | 61 | 0.030 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2013 | 98 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2015 | 1039 | 0.030 |
Why?
|
| Receptors, Cell Surface | 1 | 2012 | 144 | 0.030 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2013 | 213 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2013 | 617 | 0.020 |
Why?
|
| Genetic Markers | 1 | 2011 | 142 | 0.020 |
Why?
|
| Information Storage and Retrieval | 1 | 2010 | 31 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2014 | 628 | 0.020 |
Why?
|
| Life Style | 1 | 2012 | 308 | 0.020 |
Why?
|
| Nerve Tissue Proteins | 1 | 2012 | 360 | 0.020 |
Why?
|
| Keratin-17 | 1 | 2009 | 1 | 0.020 |
Why?
|
| Receptors, Laminin | 1 | 2009 | 2 | 0.020 |
Why?
|
| Gene Expression | 1 | 2012 | 674 | 0.020 |
Why?
|
| Cell Adhesion Molecules | 1 | 2009 | 75 | 0.020 |
Why?
|
| Disease Outbreaks | 1 | 2010 | 155 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2009 | 337 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2009 | 259 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2009 | 623 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2013 | 2231 | 0.020 |
Why?
|
| Diet | 1 | 2012 | 801 | 0.020 |
Why?
|
| Mycobacterium chelonae | 1 | 2005 | 2 | 0.020 |
Why?
|